Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

132.65 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 180
Open 132.65
Bid (Size) 132.30 (1)
Ask (Size) 133.94 (1)
Prev. Close 132.65
Today's Range 132.65 - 132.65
52wk Range 110.03 - 206.70
Shares Outstanding 145,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study
Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus. 
Via Benzinga
Reflecting On Therapeutics Stocks’ Q2 Earnings: Moderna (NASDAQ:MRNA)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at therapeutics stocks, starting with Moderna... 
Via StockStory
Topics Artificial Intelligence

Performance

YTD
-11.6%
-11.6%
1 Month
+3.7%
+3.7%
3 Month
-0.1%
-0.1%
6 Month
-5.2%
-5.2%
1 Year
-35.0%
-35.0%

More News

Read More
UK Regulator Approves Biogen’s Drug For Treating Postnatal Depression
Via Stocktwits
1 S&P 500 Stock on Our Watchlist and 2 Facing Headwinds
Via StockStory
Topics Stocks
Analyst Expectations For Biogen's Future
Via Benzinga
Meta, Microsoft Power Wall Street To New Records Despite Inflation Jump: What's Moving Markets Thursday?
Via Benzinga
Topics Economy
S&P 500 Losers: 22 Stocks With Negative Returns Over Past 10 Years, And This One's Getting The Boot
Via Benzinga
Topics Stocks
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
From Biogen Inc.
Via GlobeNewswire
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
From Biogen Inc.
Via GlobeNewswire
J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs
Via Benzinga
Topics Government World Trade
2 Cash-Producing Stocks with Exciting Potential and 1 We Ignore
Via StockStory
Q2 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Wondering what's happening in today's S&P500 pre-market session?
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Q2 Rundown: Gilead Sciences (NASDAQ:GILD) Vs Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know
Via StockStory
Topics Economy
How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment
Via Benzinga
Exploring the top movers within the S&P500 index during today's session.
Via Chartmill
BIIB Q2 Deep Dive: New Launches Offset Legacy Pressure, Pipeline Advancements Drive Guidance
Via StockStory
Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
Beyond The Numbers: 8 Analysts Discuss Biogen Stock
Via Benzinga
Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate
Via Benzinga

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 132.65
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 08/28/25 04:00 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 19.34B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 19B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.